Alder Biopharmaceuticals Overview
- Year Founded
-
2004
- Status
-
Acquired/Merged
- Employees
-
202
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.46B
Alder Biopharmaceuticals General Information
Description
Alder BioPharmaceuticals Inc is a biotechnology company that seeks to discover, develop, and commercialize therapeutic antibodies. The company's antibody platform seeks to maximize efficacy, as well as the speed of onset and durability of therapeutic response. Alder's product pipeline addresses diseases where patients have limited medical options or where current medical options may not meet the needs of a substantial number of patients. The company operates in three geographic regions: the United States, Australia, and Ireland. The vast majority of the Alder's assets are located in the United States, where the vast majority of its revenue is also generated.
Contact Information
Website
www.alderbio.comCorporate Office
- 11804 North Creek Parkway South
- Bothell, WA 98011
- United States
Corporate Office
- 11804 North Creek Parkway South
- Bothell, WA 98011
- United States
Alder Biopharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 16. Merger/Acquisition | 22-Oct-2019 | $1.46B | Completed | Generating Revenue | ||
| 15. PIPE | 10-Apr-2019 | Completed | Generating Revenue | |||
| 14. Secondary Transaction - Open Market | 31-Mar-2018 | Completed | Generating Revenue | |||
| 13. Secondary Transaction - Open Market | 31-Mar-2017 | Completed | Generating Revenue | |||
| 12. 2PO | 06-Apr-2016 | Completed | Generating Revenue | |||
| 11. Secondary Transaction - Open Market | 31-Jan-2016 | Completed | Generating Revenue | |||
| 10. PIPE | 03-Aug-2015 | Completed | Generating Revenue | |||
| 9. 2PO | 01-Jun-2015 | Completed | Generating Revenue | |||
| 8. IPO | 08-May-2014 | $80M | $207M | Completed | Generating Revenue | |
| 7. Later Stage VC (Series D) | 16-Apr-2012 | $43.9M | $127M | Completed | Clinical Trials - Phase 1 |
Alder Biopharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | 25,061,538 | $0.000100 | 6% | $3.58 | $3.58 | 1x | $3.58 | 20.8% |
| Series A | 20,736,509 | $0.000100 | 6% | $3.16 | $3.16 | 1x | $3.16 | 17.21% |
Alder Biopharmaceuticals Comparisons
Industry
Financing
Details
Alder Biopharmaceuticals Competitors (47)
One of Alder Biopharmaceuticals’s 47 competitors is Precigen, a Formerly VC-backed company based in Germantown, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Precigen | Formerly VC-backed | Germantown, MD | ||||
| Valneva | Formerly VC-backed | Lyon, France | ||||
| Vir Biotechnology | Formerly VC-backed | San Francisco, CA | ||||
| AbCellera Biologics | Formerly VC-backed | Vancouver, Canada | ||||
| Aquapharm Biodiscovery | Formerly VC-backed | Oban, United Kingdom |
Alder Biopharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Alder Biopharmaceuticals Patents
Alder Biopharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20170114122-A1 | Regulation of glucose metabolism using anti-cgrp antibodies | Inactive | 23-Oct-2015 | ||
| US-10844116-B2 | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia | Active | 16-Apr-2015 | ||
| US-20160361441-A1 | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia | Active | 16-Apr-2015 | ||
| US-20160376363-A1 | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia | Active | 16-Apr-2015 | ||
| US-20200317772-A1 | Anti-acth antibodies and use thereof | Active | 20-Feb-2014 | C07K16/26 |
Alder Biopharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Alder Biopharmaceuticals Former Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BB Biotech | Asset Manager | Minority | ||
| Bristol-Myers Squibb | Corporation | Minority | ||
| Delphi Ventures (California) | Venture Capital | Minority | ||
| Five Corners Capital | Venture Capital | Minority | ||
| Foresite Capital | Growth/Expansion | Minority |
Alder Biopharmaceuticals Investments (1)
Alder Biopharmaceuticals’s most recent deal was a Later Stage VC with Macrogenics for . The deal was made on 01-Feb-2011.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Macrogenics | 01-Feb-2011 | Later Stage VC | Drug Discovery |
Alder Biopharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Alder Biopharmaceuticals FAQs
-
When was Alder Biopharmaceuticals founded?
Alder Biopharmaceuticals was founded in 2004.
-
Where is Alder Biopharmaceuticals headquartered?
Alder Biopharmaceuticals is headquartered in Bothell, WA.
-
What is the size of Alder Biopharmaceuticals?
Alder Biopharmaceuticals has 202 total employees.
-
What industry is Alder Biopharmaceuticals in?
Alder Biopharmaceuticals’s primary industry is Drug Discovery.
-
Is Alder Biopharmaceuticals a private or public company?
Alder Biopharmaceuticals is a Private company.
-
What is the current valuation of Alder Biopharmaceuticals?
The current valuation of Alder Biopharmaceuticals is .
-
What is Alder Biopharmaceuticals’s current revenue?
The current revenue for Alder Biopharmaceuticals is .
-
How much funding has Alder Biopharmaceuticals raised over time?
Alder Biopharmaceuticals has raised $377M.
-
Who are Alder Biopharmaceuticals’s investors?
BB Biotech, Bristol-Myers Squibb, Delphi Ventures (California), Five Corners Capital, and Foresite Capital are 5 of 14 investors who have invested in Alder Biopharmaceuticals.
-
Who are Alder Biopharmaceuticals’s competitors?
Precigen, Valneva, Vir Biotechnology, AbCellera Biologics, and Aquapharm Biodiscovery are some of the 47 competitors of Alder Biopharmaceuticals.
-
When was Alder Biopharmaceuticals acquired?
Alder Biopharmaceuticals was acquired on 22-Oct-2019.
-
Who acquired Alder Biopharmaceuticals?
Alder Biopharmaceuticals was acquired by H. Lundbeck.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
